Ocular myasthenia gravis: response to long-term immunosuppressive treatment.
نویسندگان
چکیده
منابع مشابه
Ocular myasthenia gravis: response to long-term immunosuppressive treatment.
OBJECTIVE Ocular myasthenia gravis is a subtype of myasthenia gravis that causes relatively mild disability, but may convert into severe generalised muscle weakness. A universal management plan for ocular myasthenia gravis has not been established. This study was performed to determine the outcome of ocular myasthenia gravis with the currently available therapeutic options. METHODS Retrospect...
متن کاملLong-term treatment of generalised myasthenia gravis with FK506 (tacrolimus).
Efficacy and safety of long term use of FK506 (2-4.5 mg/day) for a maximum of two years were evaluated in 12 patients with generalised myasthenia gravis (MG). At the end of the study, eight patients (67%) showed improvement in either MG score or Activities in Daily Living score, and prednisolone dosage could be reduced in seven patients (58%), with a mean reduction ratio of 37%. Long term use o...
متن کاملLong term treatment of myasthenia gravis with azathioprine.
Twenty-seven patients with myasthenia gravis have been treated with azathioprine in conjunction with pyridostigmine and prednisolone for a total of 138 patient years. Side effects necessitated discontinuation of treatment in only four patients. Treatment with azathioprine was associated with marked clinical improvement in all the remaining 23 patients, resulting in reduction in the dose of pyri...
متن کاملLong-term treatment of refractory myasthenia gravis with subcutaneous immunoglobulin
Introduction Myasthenia gravis (MG) is an autoimmune disease characterized by fatigue and weakness of skeletal muscles. Laryngeal myasthenia (when dysphonia is the initial and primary complaint) is a rare variant of MG (0.46%),1 which may provide a diagnostic challenge. Although with adequate treatment majority of myasthenic patients can live productive lives with no or few symptoms, there is a...
متن کاملOcular Manifestations of Myasthenia Gravis
The cause of the weakness is due to a defect at the level of the neuromuscular junction in which autoimmune antibodies block the receptors responsible for initiating muscular contraction. The neurotransmitter that is subject to this competitive inhibition is acetylcholine (ACh). The muscles commonly affected include those of the neck, limbs and chest cavity with regards to breathing. The muscle...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Neurology, Neurosurgery & Psychiatry
سال: 1997
ISSN: 0022-3050
DOI: 10.1136/jnnp.62.2.156